Autoantibody signature differentiates Wilms tumor patients from neuroblastoma patients

PLoS One. 2011;6(12):e28951. doi: 10.1371/journal.pone.0028951. Epub 2011 Dec 16.


Several studies report autoantibody signatures in cancer. The majority of these studies analyzed adult tumors and compared the seroreactivity pattern of tumor patients with the pattern in healthy controls. Here, we compared the autoimmune response in patients with neuroblastoma and patients with Wilms tumor representing two different childhood tumors. We were able to differentiate untreated neuroblastoma patients from untreated Wilms tumor patients with an accuracy of 86.8%, a sensitivity of 87.0% and a specificity of 86.7%. The separation of treated neuroblastoma patients from treated Wilms tumor patients' yielded comparable results with an accuracy of 83.8%. We furthermore identified the antigens that contribute most to the differentiation between both tumor types. The analysis of these antigens revealed that neuroblastoma was considerably more immunogenic than Wilms tumor. The reported antigens have not been found to be relevant for comparative analyses between other tumors and controls. In summary, neuroblastoma appears as a highly immunogenic tumor as demonstrated by the extended number of antigens that separate this tumor from Wilms tumor.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Antigens, Neoplasm / immunology
  • Area Under Curve
  • Autoantibodies / immunology*
  • Child, Preschool
  • Clone Cells
  • Diagnosis, Differential
  • Humans
  • Neuroblastoma / blood
  • Neuroblastoma / diagnosis*
  • Neuroblastoma / immunology*
  • Neuroblastoma / therapy
  • Wilms Tumor / blood
  • Wilms Tumor / diagnosis*
  • Wilms Tumor / immunology*
  • Wilms Tumor / therapy


  • Antigens, Neoplasm
  • Autoantibodies